| |
MESSAGE _ENGLISH VERSION_
|
|
| |
Preclinical data on Synthetic Lethality Programs to be presented at the
2025 AACR Annual Meeting
The Management Board of Ryvu Therapeutics S.A., headquartered in Kraków
_the "Company," "Ryvu"_, announces that the Company will present
preclinical data from its' Synthetic Lethality Platform and PRMT5
project at the AACR 2025 Annual Meeting, which will take place on April
23-30, 2025, in Chicago, United States.
Details on the abstract presentation are as follows:
Abstract Title:"Preclinical candidate RVU305, an MTA-cooperative PRMT5
inhibitor,
shows activity in MTAP-deleted tumors resistant to immune checkpoint
treatment"
Session Name: HDAC and Methyltransferase Inhibitors
Session date and time:Tuesday, April 29, 9:00 AM - 12:00 PM EST
Poster Number:17 _board number_, abstract number 4231
RVU305, a potentially best-in-class, brain-permeable MTA-cooperative
PRMT5 inhibitor, demonstrates significant potential in targeting
MTAP-deleted cancers. In preclinical studies, RVU305 effectively
inhibited tumor growth in MTAP-null cancer models without affecting
normal cells. Co-treatment with an anti-PD-1 antibody was well tolerated
and resulted in antitumor activity in an MTAP-deleted, immune checkpoint
inhibitors resistant model. The effects of RVU305, both alone and in
combination with anti-PD-1, were supported by pharmacodynamic changes
observed in tumor tissue. These results position RVU305 as a promising
therapeutic option for patients carrying MTAP-deleted cancers resistant
to immune checkpoint inhibitors treatment.
Abstract Title:"Discovery of novel synthetic lethal targets for
effective and safe colorectal
cancer therapies"
Session Name: Experimental and Molecular Therapeutics
Session date and time:Monday, April 28, 2:00 PM - 5:00 PM EST
Poster Number: 3 _board number_, abstract number 2973
This study highlights the discovery and validation of novel therapeutic
targets for colorectal cancer _CRC_ through synthetic lethal _SL_
interactions, aiming to address the urgent need for more effective
treatments. By using advanced models, including genetically engineered
human intestinal stem cells _hISCs_ and patient-derived xenografts
_PDXs_, combined with CRISPR/Cas9 technology, the team identified key
vulnerabilities in CRC cells. Genome-wide screens revealed SL targets,
particularly in genes associated with APC and KRAS mutations. These
findings were validated both in vitro and in vivo, paving the way for
the development of new, targeted therapies for CRC patients based on
their unique mutational profiles.
Disclaimer: This English language translation has been prepared solely
for the convenience of English-speaking readers. Despite all the efforts
devoted to this translation, certain discrepancies, omissions or
approximations may exist. In case of any differences between the Polish
and the English versions, the Polish version shall prevail. Ryvu
Therapeutics S.A., its representatives and employees decline all
responsibility in this regard.
|
|
|
RB: Prezentacja danych przedklinicznych dla platformy ONCO Prime na dorocznym zjeździe
AACR 2026 / Preclinical data on the ONCO Prime platform to be presented at the 2026
AACR Annual Meeting
